Sauter Edward R
Department of Surgery, Hartford Hospital and University of Connecticut School of Medicine, Hartford, USA.
Eur J Breast Health. 2017 Oct 1;13(4):162-167. doi: 10.5152/ejbh.2017.3635. eCollection 2017 Oct.
Breast cancer is the most frequent cancer detected throughout both the developing and the developed world. Its incidence is on the rise in the developing world. Great strides have been made in developing biomarkers to guide therapy for women diagnosed with breast cancer. Far fewer advances have occurred with biomarker development for the early diagnosis of breast cancer. Standard screening for new and recurrent breast cancer involves clinical breast exam and breast imaging. There are no Food and Drug Administration (FDA) approved noninvasive body fluid tests for the early detection of new or recurrent breast cancer. Promising biomarker approaches include multianalyte testing of tissue for individuals diagnosed with breast cancer and body fluid analysis for both at risk women and to monitor individuals after treatment.
乳腺癌是在发展中国家和发达国家中检出率最高的癌症。在发展中国家，其发病率呈上升趋势。在开发用于指导乳腺癌确诊女性治疗的生物标志物方面已取得了长足进展。而在用于乳腺癌早期诊断的生物标志物开发方面进展则少得多。对新发和复发性乳腺癌的标准筛查包括临床乳腺检查和乳腺成像。目前尚无美国食品药品监督管理局（FDA）批准的用于早期检测新发或复发性乳腺癌的非侵入性体液检测方法。有前景的生物标志物方法包括对乳腺癌确诊个体进行组织多分析物检测，以及对高危女性进行体液分析并在治疗后监测个体。
